MacPlus Federated Search is being upgraded to ACCESSSS Smart Search!

MacPlus Federated Search is in the process of being shut down. Its new and better successor, ACCESSSS Smart Search, will operate in its place.

An automated system can transfer your account to ACCESSSS Smart Search. To complete the transfer, which will migrate information such as your user profile, alert settings, saved articles, and recently alerted articles, simply enter your email and password below.


If you don't want to migrate your user account to ACCESSSS Smart Search that's cool too -- rest assured that when MacPlus Federated Search is completely shut down we will delete your user profile and all related data from our servers.

NB: This means you only have a limited amount of time to take us up on our offer of a one-click migration of all your MacPlus Federated Search user data to ACCESSSS Smart Search, so if you're on the fence, hurry up and decide!

Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018 Apr 17;319(15):1580-1591. doi: 10.1001/jama.2018.3024.
Area Score
Family Medicine (FM)/General Practice (GP)
General Internal Medicine-Primary Care(US)
Endocrine
Internal Medicine
Abstract

Importance: The comparative clinical efficacy of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) inhibitors for treatment of type 2 diabetes is unknown.

Objective: To compare the efficacies of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on mortality and cardiovascular end points using network meta-analysis.

Data Sources: MEDLINE, Embase, Cochrane Library Central Register of Controlled Trials, and published meta-analyses from inception through October 11, 2017.

Study Selection: Randomized clinical trials enrolling participants with type 2 diabetes and a follow-up of at least 12 weeks were included, for which SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors were compared with either each other or placebo or no treatment.

Data Extraction and Synthesis: Data were screened by 1 investigator and extracted in duplicate by 2 investigators. A Bayesian hierarchical network meta-analysis was performed.

Main Outcomes and Measures: The primary outcome: all-cause mortality; secondary outcomes: cardiovascular (CV) mortality, heart failure (HF) events, myocardial infarction (MI), unstable angina, and stroke; safety end points: adverse events and hypoglycemia.

Results: This network meta-analysis of 236 trials randomizing 176?310 participants found SGLT-2 inhibitors (absolute risk difference [RD], -1.0%; hazard ratio [HR], 0.80 [95% credible interval {CrI}, 0.71 to 0.89]) and GLP-1 agonists (absolute RD, -0.6%; HR, 0.88 [95% CrI, 0.81 to 0.94]) were associated with significantly lower all-cause mortality than the control groups. SGLT-2 inhibitors (absolute RD, -0.9%; HR, 0.78 [95% CrI, 0.68 to 0.90]) and GLP-1 agonists (absolute RD, -0.5%; HR, 0.86 [95% CrI, 0.77 to 0.96]) were associated with lower mortality than were DPP-4 inhibitors. DPP-4 inhibitors were not significantly associated with lower all-cause mortality (absolute RD, 0.1%; HR, 1.02 [95% CrI, 0.94 to 1.11]) than were the control groups. SGLT-2 inhibitors (absolute RD, -0.8%; HR, 0.79 [95% CrI, 0.69 to 0.91]) and GLP-1 agonists (absolute RD, -0.5%; HR, 0.85 [95% CrI, 0.77 to 0.94]) were significantly associated with lower CV mortality than were the control groups. SGLT-2 inhibitors were significantly associated with lower rates of HF events (absolute RD, -1.1%; HR, 0.62 [95% CrI, 0.54 to 0.72]) and MI (absolute RD, -0.6%; HR, 0.86 [95% CrI, 0.77 to 0.97]) than were the control groups. GLP-1 agonists were associated with a higher risk of adverse events leading to trial withdrawal than were SGLT-2 inhibitors (absolute RD, 5.8%; HR, 1.80 [95% CrI, 1.44 to 2.25]) and DPP-4 inhibitors (absolute RD, 3.1%; HR, 1.93 [95% CrI, 1.59 to 2.35]).

Conclusions and Relevance: In this network meta-analysis, the use of SGLT-2 inhibitors or GLP-1 agonists was associated with lower mortality than DPP-4 inhibitors or placebo or no treatment. Use of DPP-4 inhibitors was not associated with lower mortality than placebo or no treatment.

Comments from MORE raters

General Internal Medicine-Primary Care(US) rater

The network meta-analysis provides general internists with the best approximation of head-to-head comparisons of the different newer agents to treat type 2 diabetes. Assuming that all other factors not included in the analysis are the same, SGLT-2 inhibitors appear to dominate the other agents. Future trials should consider the marginal contribution of SGLT-2 inhibitors after metformin. I do not believe most general internists know this information, and it could shape conversations about second- or third-line therapy for patients with type 2 diabetes.

Internal Medicine rater

Might be useful as we select our second agent after starting metformin.

Internal Medicine rater

This meta-analysis confirms what is already evident from several large trials, namely that the SGLT2 inhibitors and the GLP drugs have a favorable impact on mortality. It is useful to have this information in one paper. I suspect this will influence clinicians to use these drugs more often as add-ons to metformin.